Synonym
PF-02341272; PF02341272; PF 02341272; PNU-100480; PNU 100480; PNU100480; U-100480; U 100480; U100480; Sutezolid.
IUPAC/Chemical Name
(S)-N-((3-(3-fluoro-4-thiomorpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
InChi Key
FNDDDNOJWPQCBZ-ZDUSSCGKSA-N
InChi Code
InChI=1S/C16H20FN3O3S/c1-11(21)18-9-13-10-20(16(22)23-13)12-2-3-15(14(17)8-12)19-4-6-24-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
SMILES Code
CC(NC[C@H]1CN(C2=CC=C(N3CCSCC3)C(F)=C2)C(O1)=O)=O
Appearance
A crystalline solid
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Sutezolid, like other oxazolidinones such as linezolid and tedizolid, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This binding prevents the formation of the initiation complex of translation, thereby halting the synthesis of bacterial proteins essential for their survival and reproduction.
In vitro activity:
Sutezolid was evaluated among other oxazolidinones (delpazolid, tedizolid, and linezolid) against various rapidly growing mycobacteria (RGM) species. The microplate alamarBlue assay determined minimum inhibitory concentrations (MICs) for 32 reference and 115 clinical strains.
Reference: Wen S, Gao X, Zhao W, Huo F, Jiang G, Dong L, Zhao L, Wang F, Yu X, Huang H. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China. Int J Infect Dis. 2021 Aug;109:253-260.
In vivo activity:
Sutezolid was investigated in non-human primates (NHPs) alongside tedizolid to predict their pharmacokinetics in humans. Administered orally to NHPs, sutezolid exhibited linear pharmacokinetics described by a one-compartment model with first-order elimination, and its active metabolite, sutezolid-M1, required an additional compartment for accurate modeling. Scaling to humans suggested reasonable prediction of tedizolid and sutezolid exposures, though sutezolid's Cmax was under-predicted.
Reference: Kim S, Scanga CA, Miranda Silva C, Zimmerman M, Causgrove C, Stein B, Dartois V, Peloquin CA, Graham E, Louie A, Flynn JL, Schmidt S, Drusano GL. Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates. Eur J Pharm Sci. 2020 Aug 1;151:105421.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
50.0 |
141.48 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
353.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Kim S, Scanga CA, Miranda Silva C, Zimmerman M, Causgrove C, Stein B, Dartois V, Peloquin CA, Graham E, Louie A, Flynn JL, Schmidt S, Drusano GL. Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates. Eur J Pharm Sci. 2020 Aug 1;151:105421. doi: 10.1016/j.ejps.2020.105421. Epub 2020 Jun 9. PMID: 32531349.
Bruinenberg P, Nedelman J, Yang TJ, Pappas F, Everitt D. Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0210821. doi: 10.1128/aac.02108-21. Epub 2022 Mar 14. PMID: 35285241; PMCID: PMC9017382.
In vitro protocol:
Wen S, Gao X, Zhao W, Huo F, Jiang G, Dong L, Zhao L, Wang F, Yu X, Huang H. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China. Int J Infect Dis. 2021 Aug;109:253-260. doi: 10.1016/j.ijid.2021.06.055. Epub 2021 Jul 1. PMID: 34216736.
In vivo protocol:
Kim S, Scanga CA, Miranda Silva C, Zimmerman M, Causgrove C, Stein B, Dartois V, Peloquin CA, Graham E, Louie A, Flynn JL, Schmidt S, Drusano GL. Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates. Eur J Pharm Sci. 2020 Aug 1;151:105421. doi: 10.1016/j.ejps.2020.105421. Epub 2020 Jun 9. PMID: 32531349.
Bruinenberg P, Nedelman J, Yang TJ, Pappas F, Everitt D. Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0210821. doi: 10.1128/aac.02108-21. Epub 2022 Mar 14. PMID: 35285241; PMCID: PMC9017382.
1. Alffenaar, J.W., van der Laan, T., Simons, S., et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob. Agents Chemother. 55(3), 1287-1289 (2011).
2. Zhang, M., Sala, C., Dhar, N., et al. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58(6), 3217-3223 (2014).
3. Loreto, E.S., Tondolo, J.S.M., Oliveira, D.C., et al. In vitro activities of miltefosine and antibacterial agents from the macrolide, oxazolidinone, and pleuromutilin classes against Pythium insidiosum and Pythium aphanidermatum. Antimicrob. Agents Chemother. 62(3), e01678-01617 (2018).
